Cornelis Melief

Add links
From Wikipedia, the free encyclopedia

Cornelis Joseph Maria Melief (born 20 January 1943) is a immunologuist[1] specialising in cancer immunology and immunotherapy, with a focus on therapeutic cancer vaccines. He is emeritus Professor, former head of the Department of Immunohematology and Blood Transfusion at the Leiden University Medical Center,[1] and Chief Scientific Officer at ISA Therapeutics in Netherlands.[2] He is known for his work in the field of cancer immunology,[1] devising new cancer therapies based on the activation of the patient's own immune system.

Early life and education[edit]

He grew up in the South of the Netherlands, in the town of Zevenbergschen Hoek [nl] and from 11 years of age onwards in Amsterdam. He received his PhD Doctorate in Medicine in 1967 from the University of Amsterdam, followed by a Medical Doctor degree in 1970 from the same university. In 1973 and 1974 he was a postdoctoral fellow at the New England Medical Center and Dana-Farber Cancer Institute in Boston.

From 1970 to 1972, Melief served as an MD Lieutenant as part of compulsory Army conscription in the Netherlands.

Career[edit]

In 1975, he joined the Netherlands Red Cross Blood Transfusion Service, as Head of Department of cell-mediated immunology. From 1975 to 1985 he became a scientific staff member of the CLB Amsterdam. In 1976, Melief was made head of the new Department of Experimental Tumour Immunology which in 1982 was renamed the Department of Cellular Immunology.

From 1985 to 1991, he worked as the Head of the Division of Immunology at the Netherlands Cancer Institute[3] in Amsterdam. In 1991, he became head of the Department of Immunohematology and blood transfusion at Leiden University Medical Center. In 2004 he co-founded and became Chief Scientific Officer at the Biotech company Immune System Activation (ISA) Pharmaceuticals[2]

Since 2012, Melief has been the CSO of ISA Pharmaceuticals and emeritus Professor at Leiden University Medical Center.

Major accomplishments[edit]

He is author of more than 550 peer-reviewed publications, cited over 71,000 times[4] and inventor on more than 30 patents and patent applications.

Major patents include:

  • 2003- Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40[5]
  • 2007 - Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses[6]

Major publications include:

  • 1998 - Published T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions which was a breakthrough in the understanding of the importance of helper T-cells in priming cytotoxic T lymphocytes.[7]
  • 2009 - Published that therapeutic vaccination with long peptides caused complete or partial regression of premalignant lesions caused by human papilloma virus type 16 (HPV16).[8]
  • 2020 – Published that strong vaccine responses against HPV16 oncogenic proteins in patients with late stage cervical cancer during chemotherapy are associated with prolonged survival.[9]

Memberships[edit]

Awards and honours[edit]

  • SOFI Prize Leiden in 1986
  • AkzoNobel Prize in 1995[13]
  • European Federation of Immunological Societies Lecture Award in 2007[14]
  • Ceppellini Lecture from the European Federation for Immunogenetics in 2009 (as Cornelisees Melief)[15]
  • William B. Coley Award from the Cancer Research Institute in 2009[16]
  • Queen Wilhelmina Research Prize from the Dutch Cancer Society in 2010
  • Cancer Immunotherapy (CIMT) organization, Mainz Germany. Lifetime Achievement Award 2017[17]
  • Honorary doctorate Mainz University, Germany, 2017[18]
  • 2018 ESMO Immuno-Oncology Award in recognition of his work studying the interactions of the immune system with cancer[19]
  • 2019 AACR-CRI Lloyd J. Old Award in Cancer Immunology[20]
  • Pedro J.Romero Service to JITC Award, 2022[21]
  • 2022 Election as Fellow of the Academy of Immuno-Oncology by the Society for Immunotherapy of Cancer (SITC)[22]

References[edit]

  1. ^ a b c "Cornelis J.M. Melief, M.D., Ph.D." Cancer Research Institute. Retrieved 2022-06-13.
  2. ^ a b "Kees Melief". ISA Therapeutics BV. Retrieved 2022-06-13.
  3. ^ "NKI | Netherlands Cancer Institute". www.nki.nl. Retrieved 2022-06-13.
  4. ^ "Profiles". scholar.google.co.uk. Retrieved 2022-06-13.
  5. ^ "US Patent Application for Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40 Patent Application (Application #20050255106 issued November 17, 2005) - Justia Patents Search". patents.justia.com. Retrieved 2022-06-13.
  6. ^ "US Patent Application for Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses Patent Application (Application #20070292449 issued December 20, 2007) - Justia Patents Search". patents.justia.com. Retrieved 2022-06-13.
  7. ^ Schoenberger, Stephen P.; Toes, Rene E. M.; van der Voort, Ellen I. H.; Offringa, Rienk; Melief, Cornelis J. M. (June 1998). "T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions". Nature. 393 (6684): 480–483. Bibcode:1998Natur.393..480S. doi:10.1038/31002. ISSN 1476-4687. PMID 9624005. S2CID 4427174.
  8. ^ Kenter GG, Welters MJ, Valentjin AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ (November 5, 2009). "Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia". New England Journal of Medicine. 361 (19): 1838–47. doi:10.1056/NEJMoa0810097. PMID 19890126.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ^ Melief CJM, Welters MJP, Vergote I, Kroep JR, Kenter GG, Ottevanger PB, Tjalma WAA, Denys H, van Poelgeest MIE, Nijman HW, Reyners AKL, Velu T, Goffin F, Lalisang RI, Loof NM, Boekestijn S, Krebber WJ, Hooftman L, Visscher S, Blumenstein BA, Stead RB, Gerritsen W, van der Berg SH (March 18, 2020). "Strong vaccines responses during chemotherapy are associated with prolonged cancer survival". Sci Transl Med. 12 (535): eaaz8235. doi:10.1126/scitranslmed.aaz8235. hdl:2268/309154. PMID 32188726. S2CID 213182500.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  10. ^ "Cancer Research". American Association for Cancer Research. Retrieved 2022-06-13.
  11. ^ "Kees Melief" (in Dutch). Royal Netherlands Academy of Arts and Sciences. Retrieved 9 December 2023.
  12. ^ "ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Honored by the Association for Cancer Immunotherapy (CIMT)". ISA Therapeutics BV. 2017-05-11. Retrieved 2022-06-13.
  13. ^ Nobel, Akzo (1995). "Akzonobel annual report 1995" (PDF). Akzo Nobel.
  14. ^ "EFIS – European Federation of Immunological Societies: EFIS-IL Lecture Award". www.efis.org. Retrieved 2022-06-13.
  15. ^ EFI, EUROPEAN FEDERATION FOR IMMUNOGENETICS (30 September 2021). "The Ceppellini Lecture" (PDF). European Federation for Immunogenetics.
  16. ^ "2009 Grace and Coley Award Winners Announced". www.newswise.com. Retrieved 2022-06-13.
  17. ^ "Lifetime Achievement". CIMT. Retrieved 2022-06-13.
  18. ^ "Prof. Dr. Cornelis Melief Receives Honorary Doctorate from Johannes Gutenberg University Mainz". ISA Therapeutics BV. 2017-10-26. Retrieved 2022-06-13.
  19. ^ "2018 ESMO Immuno-Oncology Award Goes to Cornelis Melief". www.urotoday.com. Retrieved 2022-06-13.
  20. ^ "Cornelis Melief Honored With AACR-CRI Award in Cancer Immunology - The ASCO Post". ascopost.com. Retrieved 2022-06-13.
  21. ^ ISA Pharmaceuticals. "Professor Melief to receive 2022 Pedro J. Romero Service to JITC Award from Society for Immunotherapy of Cancer". Cision PR Newswire (Press release). PR Newswire. Retrieved 2023-06-13.
  22. ^ "SITC press release". July 2022.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cornelis_Melief&oldid=1221880755"